Last $5.14 USD
Change Today +0.03 / 0.59%
Volume 309.2K
ENZ On Other Exchanges
Symbol
Exchange
New York
Munich
As of 8:04 PM 10/30/14 All times are local (Market data is delayed by at least 15 minutes).

enzo biochem inc (ENZ) Snapshot

Open
$5.10
Previous Close
$5.11
Day High
$5.18
Day Low
$5.07
52 Week High
09/2/14 - $6.13
52 Week Low
11/15/13 - $2.27
Market Cap
228.8M
Average Volume 10 Days
162.8K
EPS TTM
$-0.17
Shares Outstanding
44.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ENZO BIOCHEM INC (ENZ)

enzo biochem inc (ENZ) Related Businessweek News

No Related Businessweek News Found

enzo biochem inc (ENZ) Details

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

433 Employees
Last Reported Date: 10/9/14
Founded in 1976

enzo biochem inc (ENZ) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $555.5K
Co Founder, President, Chief Financial Office...
Total Annual Compensation: $492.7K
Vice President of Corporate Development and I...
Total Annual Compensation: $215.0K
Vice President of Business Development and Ch...
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2013.

enzo biochem inc (ENZ) Key Developments

Enzo Biochem Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended July 31, 2014

Enzo Biochem Inc. announced unaudited earnings results for the fourth quarter and full year ended July 31, 2014. For the quarter, the company reported total revenues of $24,907,000 against $23,269,000 a year ago. Loss before income taxes was $3,162,000 against $3,532,000 a year ago. Net loss was $3,169,000 against $3,102,000 a year ago. Basic and diluted loss per share was $0.07 against $0.08 a year ago. Non-GAAP net loss was $2,772,000 or $0.06 basic and diluted per share against $3,102,000 or $0.08 basic and diluted per share a year ago. LBITDA was $2,160,000 against $2,395,000 a year ago. Adjusted LBITDA was $1,763,000 against $2,395,000 a year ago. Operating cash flow for the fourth quarter was a $1.0 million compared to a use of $1.5 million in the prior year period, reflecting an improvement in business performance. For the year, the company reported total revenues of $95,947,000 against $93,707,000 a year ago. Loss before income taxes was $9,905,000 against $18,949,000 a year ago. Net loss was $9,977,000 against $18,237,000 a year ago. Basic and diluted loss per share was $0.23 against $0.46 a year ago. Non-GAAP net loss was $11,217,000 or $0.26 basic and diluted per share against $18,237,000 or $0.46 basic and diluted per share a year ago. LBITDA was $5,726,000 against $14,290,000 a year ago. Adjusted LBITDA was $6,966,000 against $14,290,000 a year ago. Operating cash flows for the year was a use of $1.7 million, compared to a use of $10.0 million in the prior year.

Enzo Biochem Inc., Q4 2014 Earnings Call, Oct 10, 2014

Enzo Biochem Inc., Q4 2014 Earnings Call, Oct 10, 2014

Enzo Biochem Inc. to Report Q4, 2014 Results on Oct 09, 2014

Enzo Biochem Inc. announced that they will report Q4, 2014 results After-Market on Oct 09, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZ:US $5.14 USD +0.03

ENZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Affymetrix Inc $8.30 USD +0.19
Computer Programs & Systems Inc $64.80 USD +0.91
HealthStream Inc $30.53 USD +1.17
Luminex Corp $19.14 USD +0.11
Merge Healthcare Inc $2.62 USD +0.15
View Industry Companies
 

Industry Analysis

ENZ

Industry Average

Valuation ENZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.3x
Price/Book 6.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZO BIOCHEM INC, please visit www.enzo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.